Related Experiment Videos
Inhibition of tumor growth by polyinosinic-polycytidylic acid
Abstract:
The synthetic double-stranded RNA, polyinosinic-cytidylic acid, inhibits the growth of some tumors in mice. Two days after implantation of a reticulum cell sarcoma, a lymphatic lymphoma, a fibrosarcoma, two leukemias, and a human adenovirus 12-induced tumor, treatment of groups of mice resulted in decreased growth rates of the tumors and increased survival times of the animals. In the two tumors tested (the reticulum cell sarcoma and the adenovirus 12-induced tumor) initiation of treatment after the tumor was grown to moderate size caused a regression of the tumor. In the case of the reticulum cell sarcoma, the tumor had not reappeared in some of the animals two months after cessation of treatment.
Insights
Polyinosinic-cytidylic acid, a synthetic double-stranded RNA, demonstrated significant anti-tumor effects in mice. This compound inhibited tumor growth, increased survival rates, and even induced regression in established tumors.
Area of Science:
- Immunology
- Oncology
- Virology
Background:
- Synthetic double-stranded RNA, such as polyinosinic-cytidylic acid (poly I:C), is known to modulate immune responses.
- Tumor growth and progression are complex processes involving immune evasion and cellular proliferation.
Purpose of the Study:
- To investigate the anti-tumor efficacy of polyinosinic-cytidylic acid in a murine model.
- To evaluate the impact of poly I:C on the growth rate and survival of various tumor types.
Main Methods:
- Mice were implanted with several types of tumors, including reticulum cell sarcoma, lymphatic lymphoma, fibrosarcoma, leukemias, and a human adenovirus 12-induced tumor.
- Polyinosinic-cytidylic acid treatment was initiated two days post-tumor implantation.
- Tumor regression was assessed in reticulum cell sarcoma and adenovirus 12-induced tumors after treatment initiation on established tumors.
Main Results:
- Polyinosinic-cytidylic acid treatment significantly decreased tumor growth rates across multiple tumor types.
- Mice treated with poly I:C exhibited increased survival times compared to control groups.
- Established reticulum cell sarcoma and adenovirus 12-induced tumors showed regression following poly I:C treatment.
- In some cases of reticulum cell sarcoma, tumors did not reappear two months after treatment cessation.
Conclusions:
- Polyinosinic-cytidylic acid exhibits potent anti-tumor activity against a range of murine tumors.
- Early and delayed administration of poly I:C can inhibit tumor growth and promote regression.
- Poly I:C represents a potential therapeutic agent for cancer treatment, warranting further investigation.